Healthcare Industry News: thrombin
News Release - July 20, 2007
Auriga Laboratories Appoints Lisa Tripodi as Vice President of Trade RelationsLOS ANGELES--(HSMN NewsFeed)--Auriga Laboratories, Inc. (OTCBB:ARGA ), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, announced today that it has appointed Lisa Tripodi to the position of Vice President of Trade Relations. Ms. Tripodi has more than twenty years experience in the healthcare industry, with extensive knowledge in supply chain development and management, specialty distribution, managed care and reimbursement in managed markets and comprehensive national account expertise.
She joins Auriga from The Medicines Company (NASDAQ: MDCO ), where she was Senior National Account Manager from 2003-2007, where she was responsible for the launch of Angiomax, a direct thrombin inhibitor. She also developed health economic strategies and programs to help the product generate $250 million in sales. Prior to The Medicines Company, she leveraged her extensive reimbursement expertise as a Director of Business development in the Health Information System markets by developing and managing third party distribution channels. Previously, she was a Regional Task Force Manager at Amgen, where she helped launch Neupogen, indicated for chemotherapy induced Neutropenia for Amgen. Her comprehensive knowledge of the healthcare industry includes Oncology, Nephrology, Cardiology and GI.
"I am pleased that we were able to attract such an experienced and accomplished healthcare executive to enhance our senior management team," said Philip S. Pesin, CEO of Auriga. "As we continue to expand our portfolio of pharmaceutical and consumer brands, Lisa's experience and expertise should prove invaluable."
Ms. Tripodi earned her BS in Business Administration from the University of Akron and was awarded her Masters in Physiology from Kent State University.
About Auriga Laboratories(TM)
Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which is designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), ExtendrylŽ, and LevallŽ families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.
The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the estimated market for nasal sprays, the development of additional products, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's ability to find and execute strategic transactions, its potential exposure to litigation, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.
Source: Auriga Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.